Private Advisor Group LLC Acquires 3,593 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Private Advisor Group LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,275 shares of the biopharmaceutical company's stock after buying an additional 3,593 shares during the period. Private Advisor Group LLC's holdings in Gilead Sciences were worth $4,289,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences in the 1st quarter valued at about $25,000. Goodman Advisory Group LLC purchased a new position in Gilead Sciences in the first quarter valued at approximately $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its stake in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares during the last quarter. Core Alternative Capital grew its stake in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. grew its position in shares of Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 1.7%

Shares of NASDAQ:GILD opened at $110.17 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The company has a fifty day simple moving average of $108.81 and a 200 day simple moving average of $105.35. The firm has a market cap of $137.04 billion, a PE ratio of 23.19, a price-to-earnings-growth ratio of 0.70 and a beta of 0.29. Gilead Sciences, Inc. has a 12-month low of $70.78 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the company posted ($1.32) earnings per share. The company's quarterly revenue was down .3% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the completion of the transaction, the chief executive officer owned 615,725 shares in the company, valued at approximately $68,006,826.25. This represents a 1.60% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,000 shares of company stock valued at $7,844,775. Company insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Nine research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.